The week in industry: Sosei suspend development of Alzheimer's therapeutic

Read our round-up of some of the breaking news from the pharmaceutical industry over the past week. This week: CRUK to transform City of London into world-leading biotherapeutics hub and Medicines Discovery Catapult secures £1M artificial intelligence funding.

Go to the profile of RxNet
Sep 20, 2018
0
0

This week's industry news: 

CRUK to invest £14M in London cancer biotherapeutics hub
NICE backs use of Novartis' Tafinlar, Mekinist combination for advanced melanoma
Medicines Discovery Catapult secures £1M backing for AI project
British chemistry professor wins Grady-Stack award for science communication
Alzheimer’s disease therapy development suspended

CRUK to invest £14M in London cancer biotherapeutics hub

Cancer Research UK (CRUK; London, UK) is set to invest £14 million to transform the City of London into a “world-leading hub for cancer biotherapeutics.” The new CRUK City of London Centre will bring together scientists from University College London, King’s College London, Queen Mary University of London and the Francis Crick Institute (all London, UK) for pioneering anticancer research.

“Our ambition is for the Centre to stimulate further economic activity in biotechnology in London as new companies are formed, and industry partners move in to translate the most promising discoveries into marketable therapies,” remarked Tariq Enver, centre lead at UCL, adding, “London’s hospitals will also become flagship centres for treating patients with these new biological therapies, setting the standard for healthcare providers all over the world.”

Read more

Back to top of page

NICE backs use of Novartis' Tafinlar, Mekinist combination for advanced melanoma

The National Institute for Health and Care Excellence (NICE) has issued guidance recommending NHS reimbursement of Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for for the adjuvant treatment of resected stage III BRAF V600 mutation-positive melanoma in adults. The treatment is to be available at a confidential discounted price, already agreed between NHS England and Novartis.

Read more

Back to top of page

Medicines Discovery Catapult secures £1M backing for AI project

Innovate UK have awarded a £1 million grant to a partnership between Optibrium (Cambridge, UK), Intellegens (Cambridge, UK) and Medicines Discovery Catapult (Cheshire, UK) to support the evolution of artificial intelligence in drug discovery. The project is to use novel ‘deep learning’ methods to create a platform to predict the ADMET of new drug candidates, harnessing the power of AI to design and test potential lead molecules.

“At Medicines Discovery Catapult we apply innovation, working alongside UK SMEs to drive the development and adoption of new approaches for the discovery and early development of new medicines. This collaborative R&D activity will allow us to do just that and the grant from Innovate UK represents an important milestone for the advancement of informatics and data science,” remarked John Overington, Chief Informatics Officer at the Medicines Discovery Catapult.

Read more

Back to top of page

British chemistry professor wins Grady-Stack award for science communication

Sir Martyn Poliakoff, Professor of Chemistry at the University of Nottingham (UK), has been announced as the 2019 recipient of the American Chemical Society’s Grady-Stack Award for Interpreting Chemistry to the Public. The distinguished professor has collaborated with Brady Haran on the production of almost 650 videos about chemistry, published on the YouTube channel Periodic Videos, as well as delivering lectures to high school students and young researchers across the globe.

“Thanks to Martyn’s tireless dedication to the creation of these highly educative YouTube videos, teachers all over the world use them to introduce and create a passion amongst school children for the beauty of chemistry,” noted Marcetta Darensbourg, Professor of Chemistry at Texas A&M University (TX, USA).

Read more

Back to top of page

Alzheimer’s disease therapy development suspended

Sosei (Japan) alongside partner Allergan (Dublin, Ireland) have voluntarily suspended the clinical development of lead candidate HTL0018318 owing to an “unexpected toxicology finding” in a study involving non-human primates. Varying dose levels of HTL0018318, which is currently in Phase I trials in the US, were being investigated when the toxicological findings arose, characterized as a rare neoplastic tumor.

Read more

Back to top of page


Find more industry news here

Go to the profile of RxNet

RxNet

A network for the drug discovery and development community, Future Science Group

Your source for the latest news and views from the fields of drug discovery and medicinal chemistry.

No comments yet.